These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8100881)

  • 1. Iatrogenic hyperlipidaemia with GM1 ganglioside.
    Roberts JW; Hoeg JM; Mouradian MM; Linfante I; Chase TN
    Lancet; 1993 Jul; 342(8863):115. PubMed ID: 8100881
    [No Abstract]   [Full Text] [Related]  

  • 2. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
    Schneider JS; Roeltgen DP; Rothblat DS; Chapas-Crilly J; Seraydarian L; Rao J
    Neurology; 1995 Jun; 45(6):1149-54. PubMed ID: 7783880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM1 ganglioside in the treatment of Parkinson's disease.
    Schneider JS
    Ann N Y Acad Sci; 1998 Jun; 845():363-73. PubMed ID: 9668369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients.
    Augustinsson LE; Blennow K; Blomstrand C; Bråne G; Ekman R; Fredman P; Karlsson I; Kihlgren M; Lehmann W; Lekman A; Månsson JE; Ramström I; Wallin A; Wikkelsö C; Gottfries CG; Svennerholm L
    Dement Geriatr Cogn Disord; 1997; 8(1):26-33. PubMed ID: 8997549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.
    Schneider JS; Roeltgen DP; Mancall EL; Chapas-Crilly J; Rothblat DS; Tatarian GT
    Neurology; 1998 Jun; 50(6):1630-6. PubMed ID: 9633704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM1 ganglioside in Parkinson's disease: Results of a five year open study.
    Schneider JS; Sendek S; Daskalakis C; Cambi F
    J Neurol Sci; 2010 May; 292(1-2):45-51. PubMed ID: 20206941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.
    Schneider JS
    Glycoconj J; 2022 Feb; 39(1):13-26. PubMed ID: 34037912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siagoside. GM1, Sygen.
    Drugs R D; 1999 Jan; 1(1):36-7. PubMed ID: 10565981
    [No Abstract]   [Full Text] [Related]  

  • 9. Parenteral administration of GM1 ganglioside to presenile Alzheimer patients.
    Svennerholm L; Gottfries CG; Blennow K; Fredman P; Karlsson I; Månsson JE; Toffano G; Wallin A
    Acta Neurol Scand; 1990 Jan; 81(1):48-53. PubMed ID: 2330815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of GM1 ganglioside following parenteral administration.
    Cornelli U; Panucci A; Zingali G; Kirschner G; Baggio C; Cogo R
    J Pharm Pharmacol; 1990 Oct; 42(10):708-11. PubMed ID: 1982143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM1 ganglioside for acute ischemic stroke. Trial design issues.
    Alter M
    Ann N Y Acad Sci; 1998 Jun; 845():391-401. PubMed ID: 9668372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM-1 ganglioside for spinal-cord injury.
    Schönhöfer PS
    N Engl J Med; 1992 Feb; 326(7):493; author reply 494. PubMed ID: 1732787
    [No Abstract]   [Full Text] [Related]  

  • 13. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
    Schneider JS; Seyfried TN; Choi HS; Kidd SK
    PLoS One; 2015; 10(12):e0143351. PubMed ID: 26629687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GM1 ganglioside treatment of focal ischemia: a dose-response and microdialysis study.
    Simon RP; Chen J; Graham SH
    J Pharmacol Exp Ther; 1993 Apr; 265(1):24-9. PubMed ID: 8474009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers.
    Rost KL; Brockmöller J; Weber W; Roots I
    Clin Pharmacol Ther; 1991 Aug; 50(2):141-9. PubMed ID: 1868675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of GM1 on Parkinson's disease in rats and its mechanism.
    Ba XH
    Int J Neurosci; 2016; 126(2):163-7. PubMed ID: 25495991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
    Schneider JS
    J Neurosci Res; 1992 Jan; 31(1):112-9. PubMed ID: 1613817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Autophagy Contributes to Protective Effects of GM1 Ganglioside Against Aβ1-42-Induced Neurotoxicity and Cognitive Deficits.
    Dai R; Zhang S; Duan W; Wei R; Chen H; Cai W; Yang L; Wang Q
    Neurochem Res; 2017 Aug; 42(8):2417-2426. PubMed ID: 28497346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of ganglioside GM1 in acute stroke.
    Appollonio I; Frattola L; Massarotti M
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):685-6. PubMed ID: 2732750
    [No Abstract]   [Full Text] [Related]  

  • 20. Is ganglioside GM1 effective in the treatment of stroke?
    Braune S
    Drugs Aging; 1991 Jan; 1(1):57-66. PubMed ID: 1794005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.